Great Novel Therapeutics Biotech & Medicals (7427.TWO) Earnings Analysis
Great Novel Therapeutics Biotech & Medicals (7427.TWO) has no confirmed upcoming earnings date. Trailing P/E -34.30.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 7427.TWO next report earnings?
No confirmed upcoming earnings date is currently scheduled for 7427.TWO. This page updates as the calendar is published.
7427.TWO earnings history — beats and misses
No reported earnings history is available for this symbol in our dataset.
7427.TWO valuation and analyst view
| Trailing P/E | -34.30 |
|---|---|
| Trailing EPS | -2.15767 TWD |
| Price / book | 6.81 |
| Dividend yield | 0.00% |
| Market cap | 2.94B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Great Novel Therapeutics Biotech & Medicals (7427.TWO)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for 7427.TWO. This page updates as the calendar is published.
What is 7427.TWO's current P/E ratio and EPS?
7427.TWO trades at a trailing P/E of -34.30 on trailing EPS of -2.157669830804888 TWD.
What do analysts rate 7427.TWO?
7427.TWO has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.